BTIG upgraded Embecta (EMBC) to Buy from Neutral with a $26 price target Shares gained about 30% in Tuesday trading as investors rewarded ...

In a report released yesterday, Kallum Titchmarsh from Morgan Stanley maintained a Sell rating on Embecta Corporation (EMBC – Research Report), ...

Kurdikar, CEO of Embecta (EMBC) said, “As our stand-up work nears completion and following an in-depth review of our ...

Embecta announced today that it discontinued its insulin patch pump program and plans to initiate a restructuring plan.

Despite winning an FDA green light nearly three months ago for its first wearable insulin delivery system, Embecta is now ...

After adding nearly 30% in the previous session following its better-than-expected Q4 results for FY24, Embecta (NASDAQ:EMBC) ...

Q4 2024 Earnings Call Transcript November 26, 2024 Embecta Corp. misses on earnings expectations. Reported EPS is $ EPS, ...

Embecta also said it expects to earn between $2.70 and $2.90 a share on an adjusted basis for all of 2025, easily surpassing the average analyst estimate of $2.27 per share. Revenue is anticipated at ...

Embecta Corp (EMBC) reports a 4.1% revenue increase while navigating restructuring and future growth opportunities.

Embecta (NASDAQ:EMBC – Get Free Report) is scheduled to release its earnings data before the market opens on Tuesday, ...

CEO Dev Kurdikar said the decision may “come as a surprise” as Embecta just received FDA clearance for a patch pump, but the company “did not intend to do a full market launch of this product.” ...

Embecta EMBC is preparing to release its quarterly earnings on Tuesday, 2024-11-26. Here's a brief overview of what investors ...